Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CABA |
---|---|---|
09:32 ET | 8108 | 10.01 |
09:34 ET | 1000 | 9.84 |
09:36 ET | 1600 | 9.995 |
09:38 ET | 496 | 9.9636 |
09:39 ET | 1155 | 10.01 |
09:41 ET | 1827 | 10.03 |
09:43 ET | 500 | 10.08 |
09:45 ET | 727 | 10.04 |
09:48 ET | 1800 | 10.05 |
09:50 ET | 1700 | 10.095 |
09:52 ET | 8513 | 10.155 |
09:54 ET | 819 | 10.24 |
09:56 ET | 7260 | 10.18 |
09:57 ET | 1727 | 10.18 |
09:59 ET | 8551 | 10.2 |
10:01 ET | 600 | 10.22 |
10:03 ET | 1647 | 10.195 |
10:06 ET | 4153 | 10.185 |
10:08 ET | 3130 | 10.2 |
10:10 ET | 1300 | 10.21 |
10:12 ET | 1100 | 10.2 |
10:14 ET | 900 | 10.19 |
10:15 ET | 2600 | 10.2 |
10:17 ET | 2323 | 10.2 |
10:19 ET | 1000 | 10.19 |
10:21 ET | 3386 | 10.25 |
10:24 ET | 2310 | 10.21 |
10:26 ET | 10330 | 10.205 |
10:28 ET | 1100 | 10.24 |
10:30 ET | 600 | 10.225 |
10:32 ET | 2809 | 10.25 |
10:33 ET | 1852 | 10.23 |
10:35 ET | 15464 | 10.21 |
10:37 ET | 1900 | 10.2 |
10:39 ET | 5305 | 10.225 |
10:42 ET | 3275 | 10.24 |
10:44 ET | 3100 | 10.195 |
10:46 ET | 1000 | 10.2125 |
10:48 ET | 3356 | 10.235 |
10:50 ET | 2500 | 10.235 |
10:51 ET | 1200 | 10.25 |
10:53 ET | 2300 | 10.22 |
10:55 ET | 1703 | 10.205 |
10:57 ET | 1600 | 10.22 |
11:00 ET | 2920 | 10.22 |
11:02 ET | 1900 | 10.23 |
11:04 ET | 2638 | 10.24 |
11:06 ET | 1100 | 10.225 |
11:08 ET | 1518 | 10.235 |
11:09 ET | 2239 | 10.22 |
11:11 ET | 1569 | 10.21 |
11:13 ET | 1100 | 10.225 |
11:15 ET | 1900 | 10.2 |
11:18 ET | 2300 | 10.175 |
11:20 ET | 3691 | 10.195 |
11:22 ET | 3313 | 10.2 |
11:24 ET | 2450 | 10.215 |
11:26 ET | 1900 | 10.22 |
11:27 ET | 700 | 10.22 |
11:29 ET | 1109 | 10.22 |
11:31 ET | 1381 | 10.215 |
11:33 ET | 2400 | 10.24 |
11:36 ET | 3080 | 10.245 |
11:38 ET | 5323 | 10.235 |
11:40 ET | 1900 | 10.215 |
11:42 ET | 900 | 10.235 |
11:44 ET | 2500 | 10.23 |
11:45 ET | 1557 | 10.24 |
11:47 ET | 800 | 10.24 |
11:49 ET | 2930 | 10.24 |
11:51 ET | 885 | 10.24 |
11:54 ET | 1300 | 10.24 |
11:56 ET | 6928 | 10.25 |
11:58 ET | 300 | 10.245 |
12:00 ET | 2473 | 10.21 |
12:02 ET | 2100 | 10.215 |
12:03 ET | 1732 | 10.23 |
12:05 ET | 794 | 10.225 |
12:07 ET | 1500 | 10.17 |
12:09 ET | 2291 | 10.19 |
12:12 ET | 2300 | 10.185 |
12:14 ET | 1100 | 10.18 |
12:16 ET | 1250 | 10.195 |
12:18 ET | 1680 | 10.2 |
12:20 ET | 800 | 10.19 |
12:21 ET | 3134 | 10.2 |
12:23 ET | 1503 | 10.19 |
12:25 ET | 1400 | 10.19 |
12:27 ET | 2326 | 10.19 |
12:30 ET | 1878 | 10.18 |
12:32 ET | 7551 | 10.175 |
12:34 ET | 2100 | 10.18 |
12:36 ET | 1750 | 10.19 |
12:38 ET | 2000 | 10.19 |
12:39 ET | 2559 | 10.175 |
12:41 ET | 900 | 10.175 |
12:43 ET | 9996 | 10.175 |
12:45 ET | 3340 | 10.18 |
12:48 ET | 1000 | 10.185 |
12:50 ET | 700 | 10.19 |
12:52 ET | 3214 | 10.18 |
12:54 ET | 800 | 10.19 |
12:56 ET | 2104 | 10.2 |
12:57 ET | 500 | 10.195 |
12:59 ET | 841 | 10.2 |
01:01 ET | 600 | 10.21 |
01:03 ET | 700 | 10.21 |
01:06 ET | 1483 | 10.2 |
01:08 ET | 1354 | 10.195 |
01:10 ET | 1466 | 10.19 |
01:12 ET | 2661 | 10.22 |
01:14 ET | 600 | 10.21 |
01:15 ET | 922 | 10.21 |
01:17 ET | 2100 | 10.19 |
01:19 ET | 1800 | 10.2 |
01:21 ET | 600 | 10.2 |
01:24 ET | 1308 | 10.2 |
01:26 ET | 900 | 10.2 |
01:28 ET | 3650 | 10.2 |
01:30 ET | 600 | 10.195 |
01:32 ET | 1637 | 10.2 |
01:33 ET | 2164 | 10.2 |
01:35 ET | 1100 | 10.205 |
01:37 ET | 5360 | 10.17 |
01:39 ET | 6100 | 10.12 |
01:42 ET | 1900 | 10.115 |
01:44 ET | 4235 | 10.15 |
01:46 ET | 10265 | 10.14 |
01:48 ET | 4365 | 10.07 |
01:50 ET | 2591 | 10.085 |
01:51 ET | 800 | 10.08 |
01:53 ET | 3591 | 10.08 |
01:55 ET | 2303 | 10.096 |
01:57 ET | 1200 | 10.095 |
02:00 ET | 1823 | 10.09 |
02:02 ET | 1100 | 10.095 |
02:04 ET | 800 | 10.095 |
02:06 ET | 2600 | 10.08 |
02:08 ET | 1500 | 10.09 |
02:09 ET | 7947 | 10.1 |
02:11 ET | 1200 | 10.07 |
02:13 ET | 2013 | 10.04 |
02:15 ET | 3256 | 10.06 |
02:18 ET | 4284 | 10.08 |
02:20 ET | 200 | 10.07 |
02:22 ET | 500 | 10.07 |
02:24 ET | 4412 | 10.12 |
02:26 ET | 2067 | 10.07 |
02:27 ET | 1087 | 10.07 |
02:29 ET | 1850 | 10.07 |
02:31 ET | 5157 | 10.07 |
02:33 ET | 5216 | 10.06 |
02:36 ET | 1000 | 10.06 |
02:38 ET | 3283 | 10.06 |
02:40 ET | 1380 | 10.06 |
02:42 ET | 3015 | 10.06 |
02:44 ET | 5795 | 10.1 |
02:45 ET | 1253 | 10.085 |
02:47 ET | 1100 | 10.085 |
02:49 ET | 894 | 10.08 |
02:51 ET | 1900 | 10.07 |
02:54 ET | 1999 | 10.06 |
02:56 ET | 1200 | 10.06 |
02:58 ET | 4520 | 10.09 |
03:00 ET | 1100 | 10.085 |
03:02 ET | 3467 | 10.085 |
03:03 ET | 2714 | 10.05 |
03:05 ET | 4204 | 9.95 |
03:07 ET | 6540 | 9.89 |
03:09 ET | 3867 | 9.9 |
03:12 ET | 3546 | 9.84 |
03:14 ET | 900 | 9.85 |
03:16 ET | 3825 | 9.88 |
03:18 ET | 400 | 9.87 |
03:20 ET | 3996 | 9.9 |
03:21 ET | 1490 | 9.89 |
03:23 ET | 500 | 9.9 |
03:25 ET | 11895 | 9.88 |
03:27 ET | 9235 | 9.925 |
03:30 ET | 1627 | 9.9 |
03:32 ET | 2041 | 9.9 |
03:34 ET | 5856 | 9.94 |
03:36 ET | 1310 | 9.97 |
03:38 ET | 1495 | 9.99 |
03:39 ET | 4393 | 9.995 |
03:41 ET | 6481 | 10.03 |
03:43 ET | 2561 | 10.025 |
03:45 ET | 8518 | 10.075 |
03:48 ET | 12684 | 10.065 |
03:50 ET | 10587 | 10.09 |
03:52 ET | 16070 | 10.105 |
03:54 ET | 13545 | 10.115 |
03:56 ET | 10073 | 10.19 |
03:57 ET | 18745 | 10.17 |
03:59 ET | 16830 | 10.19 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cabaletta Bio Inc | 491.9M | -5.9x | --- |
Kalvista Pharmaceuticals Inc | 492.3M | -3.7x | --- |
Neurogene Inc | 488.1M | -8.2x | --- |
Aerovate Therapeutics Inc | 502.7M | -5.8x | --- |
Compass Pathways PLC | 504.7M | -3.1x | --- |
Nkarta Inc | 478.5M | -2.9x | --- |
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $491.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.47 |
EPS | $-1.73 |
Book Value | $4.94 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.